Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Huashi Jiedu Fang is a Traditional Chinese Medicine (TCM) herbal formula developed by the Affiliated Hospital of Integrated Traditional Chinese and Western Medicine at Nanjing University of Chinese Medicine, specifically for the treatment of COVID-19. The formula is designed based on the TCM principles of 'Yiqi' (supplementing Qi), 'Huashi' (resolving dampness), and 'Jiedu' (detoxification) to address the 'damp-toxin pestilence' associated with SARS-CoV-2 infection. It is primarily indicated for patients with mild to moderate COVID-19 to alleviate symptoms such as fever, cough, and fatigue, and to prevent the progression to severe illness. The mechanism of action involves multi-component and multi-target effects, including the modulation of the host immune response by suppressing pro-inflammatory cytokines like Interleukin-6 (IL-6) and Tumor Necrosis Factor (TNF), and potentially inhibiting viral entry or replication pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqi Huashi Jiedu Fang.